著者
Sho FUKUI Norihiko OOYAMA Jun TAMURA Mohammed Ahmed UMAR Tomohito ISHIZUKA Takaharu ITAMI Kenjiro MIYOSHI Tadashi SANO Kazuto YAMASHITA
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.15-0666, (Released:2017-01-21)
被引用文献数
14

Maropitant, a neurokinin-1 receptor antagonist, may provide analgesic effects by blocking pharmacological action of substance P. Carprofen is a non-steroidal anti-inflammatory drug commonly used for pain control in dogs. The purpose of this study was to evaluate the effect of a combination of maropitant and carprofen on the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs. Six healthy adult beagle dogs were anesthetized with sevoflurane four times with a minimum of 7-day washout period. On each occasion, maropitant (1 mg/kg) alone, carprofen (4 mg/kg) alone, a combination of maropitant (1 mg/kg) and carprofen (4 mg/kg), or saline (0.1 ml/kg) was subcutaneously administered at 1 hr prior to the first electrical stimulation for the sevoflurane MAC-BAR determination. The sevoflurane MAC-BAR was significantly reduced by maropitant alone (2.88 ± 0.73%, P=0.010), carprofen alone (2.96 ± 0.38%, P=0.016) and the combination (2.81 ± 0.51%, P=0.0003), compared with saline (3.37 ± 0.56%). There was no significant difference in the percentage of MAC-BAR reductions between maropitant alone, carprofen alone and the combination. The administration of maropitant alone and carprofen alone produced clinically significant sparing effects on the sevoflurane MAC-BAR in dogs. However, the combination of maropitant and carprofen did not produce any additive effect on the sevoflurane MAC-BAR reduction. Anesthetic premedication with a combination of maropitant and carprofen may not provide the sparing effect on anesthetic requirement in dogs.
著者
山下 和人 安達 洋平 久代 季子 Mohammed Ahmed UMAR 都築 圭子 前原 誠也 瀬野 貴弘 泉澤 康晴
出版者
公益社団法人 日本獣医師会
雑誌
日本獣医師会雑誌 (ISSN:04466454)
巻号頁・発行日
vol.57, no.11, pp.715-720, 2004-11-20 (Released:2011-06-17)
参考文献数
22
被引用文献数
1 1

犬臨床例にプロポフォール (P) とフェンタニル (F) を併用した全静脈麻酔 (PF-TIVA) を応用した. 麻酔前投薬としてプロピオニールプロマジン0.05mg/kg, ドロペリドール0.25mg/kg, ミダゾラム0.3mg/kg, またはメデトミジン5μg/kgを静脈内投与 (IV) し, Pで麻酔導入した. Fを2μg/kgIV後に0.2μg/kg/分で持続IVし, PのIV投与速度を調節して外科麻酔を維持した. 麻酔維持に要したP投与速度はメデトミジンの麻酔前投薬で0.2~0.3mg/kg/分, その他で0.3~0.4mg/kg/分であった. PF-TIVAでは呼吸抑制が強く調節呼吸の必要性が高かったが, 循環抑制は少なく, 外科手術も円滑に進行し, 麻酔回復も穏やかであった. PF-TIVAは犬の全身麻酔法として有用と考えられた.
著者
Hisashi SAKATA Yushun ISHIKAWA Genki ISHIHARA Norihiko OYAMA Takaharu ITAMI Mohammed Ahmed UMAR Tadashi SANO Kazuto YAMASHITA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.18-0479, (Released:2019-01-30)
被引用文献数
7

This study evaluated the effect of sevoflurane anesthesia on neuromuscular blockade with rocuronium in dogs. Six healthy beagle dogs were anesthetized four times with a minimum 14-day washout period. On each occasion, the dogs were administered 1.25-, 1.5-, 1.75-, or 2.0-fold of the individualized minimum alveolar concentration (MAC) of sevoflurane and received an infusion of rocuronium (0.5 mg/kg followed by 0.2 mg/kg/h) for 120 min. Neuromuscular function was monitored with acceleromyography and train-of-four (TOF) stimulation of the left hind limb. Time to achieve TOF count 0 (onset time), time from the onset of neuromuscular blockade to the reappearance of TOF count 4 (blockade period), and time from the onset of rocuronium infusion to attaining a 70 or 90% TOF ratio (TOFR70 or TOFR90) were recorded. There were no significant differences in the onset time, blockade period, and plasma rocuronium concentration between the sevoflurane MAC multiples. The TOFR70 and TOFR90 were dose-dependently prolonged with the sevoflurane MAC multiples. There were significant differences in the TOFR70 and TOFR90 between the 1.25 sevoflurane MAC (median: 55 and 77.5 min, respectively) and 1.75 sevoflurane MAC (122.0 and 122.6 min; P=0.020 and P=0.020, respectively), 1.25 sevoflurane MAC and 2.0 sevoflurane MAC (126.0 and 131.4 min; P=0.020 and P=0.020), and 1.5 sevoflurane MAC (97.5 and 121.3 min) and 2.0 sevoflurane MAC (P=0.033 and P=0.032). In dogs, sevoflurane anesthesia produced dose-dependent prolongation of recovery from neuromuscular blockade produced by rocuronium.
著者
Norihiko OYAMA Tadashi SANO Mizuki YAMAMORI Jun TAMURA Mohammed Ahmed UMAR Yusuke ENDO Yusyun ISHIKAWA Akifumi ITOH Kenjirou MIYOSHI Kazuto YAMASHITA
出版者
JAPANESE SOCIETY OF VETERINARY SCIENCE
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.17-0356, (Released:2018-08-03)
被引用文献数
1

Robenacoxib is a novel nonsteroidal anti-inflammatory drug approved for dogs. The present study aimed to evaluate influences of sevoflurane anesthesia on the distribution of robenacoxib in dogs. Ten healthy beagle dogs (1 to 11 years old, 9.3 to 14.3 kg body weight, 6 males and 4 females) were subcutaneously administered robenacoxib (2 mg/kg) under conscious condition or sevoflurane anesthesia inhaled a 1.3-fold predetermined individual minimum alveolar concentration of sevoflurane at a 28-day interval. The dogs under sevoflurane anesthesia were also mechanically ventilated and received fluid-therapy. On each occasion, serum samples were collected from the dogs before and at 5, 15, 30, 60, 120, 180 and 240 min after the robenacoxib administration. Serum robenacoxib concentration was measured by a liquid chromatography-tandem mass spectrometry. Maximum serum concentration of robenacoxib (Cmax) was 2.2 μg/ml [range: 1.2–4.6] (median [range: minimum–maximum]) and time of Cmax (Tmax) was 90 min [range: 60–120] in the conscious dogs. In the sevoflurane-anesthetized dogs, the Cmax significantly declined (1.3 μg/ml [range: 0.8–1.4], P=0.008) and Tmax was delayed (120 min [range: 120–240], P=0.018) compared with those in the conscious dogs. The serum robenacoxib concentration at 240 min (C240) decreased to 0.5 μg/ml [range: 0.2–0.9] in the conscious dogs, while it remained higher in the sevoflurane-anesthetized dogs (1.0 μg/ml [range: 0.3–1.4], P=0.011). In conclusion, the anesthetic procedure with sevoflurane, mechanically ventilated, and received fluid-therapy might affect the pharmacokinetics of subcutaneously administered robenacoxib in dogs.